Caris Life Sciences Posts 79% Q1 Revenue Growth to $216.2M, Gets Perform Rating
CAI•Caris Life Sciences reported Q1 2026 revenue of $216.2 million, a 79% year-over-year increase driven by molecular profiling services. Despite record revenue growth, the company’s shares hit a new 52-week low and received a Perform rating from New Street.
1. Q1 Revenue Jump and Performance Drivers
Caris Life Sciences delivered total revenue of $216.2 million in Q1 2026, up 79% year-over-year, led by strong demand for its molecular profiling services and the Caris Assure® test.
2. Stock Pressure and Perform Rating
The stock fell sharply to a new 52-week low, reflecting significant downward pressure, as New Street initiated coverage with a Perform rating indicating expectations of in-line market performance.
3. Caris Assure® New York Expansion
The company applied to the New York State Department of Health for its Caris Assure® blood-based biomarker test, underscoring continued investment in geographic and product expansion.
